Actualización del uso de anticonceptivos en el tratamiento de la endometriosis

R. Triano-Sánchez, L. de Prado-Prieto
In: SEMERGEN - Medicina de Familia · 2011 · vol. 38(2) , pp. 95–101 · doi:10.1016/j.semerg.2011.09.004 · W1965437217
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This paper reviews the use of contraceptives in endometriosis treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis has a prevalence of about 10% and benefits from hormonal contraceptive treatment. It is a chronic and recurrent illness that occurs in fertile women, and is characterised by ectopic endometrial tissue. Clinical manifestations are: infertility, pain and pelvic mass. The goals of the treatment are: relief of symptoms, prevention of progression of disease and the stimulation of fertility. Current treatment options are: Expectant management, analgesia, hormonal therapy, surgery and combined therapies. The use of combined contraceptives is associated with a reduced risk of developing endometriosis, they are also a good choice to prevent pregnancy, and for women with minimal or mild symptoms. Progestins are used for symptomatic endometriosis and as an adjuvant to surgery. The combined contraceptives and the progestins must be considered as a first line treatment.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (37)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-08-22T06:23:50.750314+00:00
License: CC0 · commercial use OK